Skip to main content

Peer Review reports

From: Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials

Original Submission
6 Mar 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
17 Jun 2023 Reviewed Reviewer Report
1 Jul 2023 Reviewed Reviewer Report
14 Jul 2023 Author responded Author comments - Chen Shi
Resubmission - Version 3
14 Jul 2023 Submitted Manuscript version 3
Publishing
3 Aug 2023 Editorially accepted
10 Oct 2023 Article published 10.1186/s12885-023-11250-1

You can find further information about peer review here.

Back to article page